Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 9, No 2 (2016) BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION Abstract  similar documents
V. R. Mkrtchyan, A. M. Sergeev, K. I. Pochigaeva, I. A. Shpak
"... Objectives. To assess the incremental budget impact (BI) of using of utilizing perampanel to treat ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk
 
Vol 6, No 3 (2013) PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk
 
Vol 8, No 1 (2015) BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD Abstract  similar documents
A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina
"... We have performed the first-ever Budget Impact Analysis (BIA) in a Russian context of bendamustine ..."
 
Vol 9, No 3 (2016) CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov
 
Vol 12, No 4 (2019) Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation Abstract  similar documents
S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev
"... . Budget impact analysis for the partial replacement of omalizumab with mepolizumab and/or reslizumab has ..."
 
Vol 14, No 2 (2021) Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis Abstract  similar documents
A. V. Rudakova, D. G. Tolkacheva, V. D. Sokolova
"... prices. The budget impact analysis of the influence of netakimab inclusion in the therapy for patients ..."
 
Vol 6, No 2 (2013) PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH CARBONIC ANHYDRASE INHIBITORS Abstract  similar documents
A. Yu. Kulikov, V. G. Serpik
"... by mean of costefficacy and budget impact analysis. Results have shown, that Azopt has benefits compare ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE Abstract  similar documents
A. U. Kulikov, I. A. Komarov
"... of this group of patients. We performed budget impact analysis on the basis of two bronchodilators in Russian ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... -effectiveness ratio (CER) and budget impact analysis (BIA) were performed. All calculations were made in the MS ..."
 
Vol 10, No 1 (2017) EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... , sorafenib 651 mg/day (after dose reduction), and chemotherapeutic agents. As part of the budget impact ..."
 
Vol 10, No 1 (2017) BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS Abstract  similar documents
E. A. Pyadushkina
 
Vol 11, No 1 (2018) Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia Abstract  similar documents
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina
"... to perform the cost-effectiveness analysis,  incremental analysis, and «budget impact» analysis. Results ..."
 
Vol 11, No 2 (2018) Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia Abstract  similar documents
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina
"... ’ medical records. The cost-effectiveness analysis, incremental analysis, and «budget impact» analysis were ..."
 
Vol 11, No 3 (2018) Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus Abstract  similar documents
A. G. Tolkushin, N. L. Pogudina
 
Vol 12, No 1 (2019) Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan Abstract  similar documents
T. P. Bezdenezhnykh, D. V. Fedyaev, G. R. Khachatryan, G. G. Arutyunov, K. V. Gerasimova
"... optimization in the Republic of Tatarstan. Materials and methods. A budget impact model was created to compare ..."
 
Vol 12, No 2 (2019) Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria Abstract  similar documents
S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova
"... . The economic assessment was made using the cost-effectiveness analysis and budget impact analysis. The cost ..."
 
Vol 12, No 4 (2019) Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer Abstract  similar documents
N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov
"... consisted of two parts: clinical and economic study and budget impact analysis. We used cost minimization ..."
 
Vol 15, No 3 (2022) Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation Abstract  similar documents
N. A. Avxentyev, Yu. V. Makarova
"... . Objective: to perform a long-term analysis of canagliflozin budget impact in adult patients with DM2 and DN ..."
 
Vol 13, No 4 (2020) Pharmacoeconomic feasibility of using the drug Hemangiol (propranolol, oral solution) in the treatment of proliferating infantile hemangioma requiring systemic therapy Abstract  similar documents
I. N. Dyakov, S. R. Varfolomeеva
"... -effectiveness analysis) with a sensitivity analysis; and a "budget impact" analysis with a sensitivity analysis ..."
 
Vol 15, No 1 (2022) Cost-effectiveness and budget impact analyses of using implantable cardioverter-defibrillators in the Russian Federation Abstract  similar documents
T. O. Bessonova, F. V. Gorkavenko, D. G. Shchurov, Yu. V. Seryapina, O. R. Chetverikova, V. V. Omelyanovskiy, S. N. Krivolapov, N. M. Neminushchiy, A. A. Kalemberg
"... Objective: to evaluate cost-effectiveness and budget impact of using single and dual chamber ..."
 
Vol 5, No 2 (2012) PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH COMBINATIONS OF PROSTAGLANDIN ANALOGUES AND BETA-BLOCKERS Abstract  similar documents
A. Yu. Kulikov, V. G. Serpikov
"... analogues and beta-blockers by mean of cost-efficacy and budget impact analysis. Results have shown ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS Abstract  similar documents
M. V. Protsenko
"... minimization and budget impact analysis was conducted. Results have shown, that Azarga has benefits compare ..."
 
Vol 6, No 4 (2013) Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation Abstract  similar documents
A. Yu. Kulikov, L. A. Komarov
"... , the results of budget impact analysis illustrate that including сerebrolysin into the standard therapy ..."
 
Vol 8, No 4 (2015) CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva
"... for the cost-minimization analysis (model 1) and analysis of the budget impact TRA usage (model 2 ..."
 
Vol 10, No 1 (2017) PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS Abstract  similar documents
A. S. Kolbin, I. A. Vilum, М. A. Proskurin, Yu. E. Balykina
"... . Recommendations to carry out a budget impact analysis in theRussian Federation (2016) were used. Results ..."
 
Vol 14, No 2 (2021) Clinical and economic analysis of using the thrombodynamics test in patients undergoing treatment with assisted reproductive technologies in the Russian Federation Abstract  similar documents
D. G. Shchurov, V. S. Dombrovskiy
 
Vol 16, No 3 (2023) Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer Abstract  similar documents
I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova
"... parameters, budget impact analysis were carried out. Results. The total medical costs for CP/EP + ATZ course ..."
 
Vol 17, No 1 (2024) Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer Abstract  similar documents
S. К. Zyryanov, I. N. Dyakov
"... ,165.00 rubles (–0.4%). The budget impact analysis showed that an increase in the proportion of patients ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of blood glucose meter Contour TS in diabetes treatment Abstract  similar documents
A. U. Kulikov, V. V. Babiy
"... research compared the cost-effectiveness and the budget impact results of using Contour TS, Accu-Chek ..."
 
Vol 10, No 2 (2017) COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA Abstract  similar documents
N. L. Pogudina, E. G. Kosolapov, F. S. Kochenkov, A. V. Karaulov, N. L. Bondarenko, D. V. Blinov
"... . Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis ..."
 
Vol 10, No 2 (2017) COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD Abstract  similar documents
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov
 
Vol 10, No 3 (2017) Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis Abstract  similar documents
E. V. Biryukova, V. I. Ignat’eva
 
Vol 15, No 2 (2022) Pharmacoeconomic analysis of the use of a fixed combination of tiotropium bromide and olodaterol as maintenance therapy in patients with chronic obstructive pulmonary disease in the Russian Federation Abstract  similar documents
S. К. Zyryanov, I. N. Dyakov
 
Vol 16, No 1 (2023) Updated clinical and economic analysis of using follitropin alfa in combination with assisted reproductive technologies in 2022 Abstract  similar documents
D. G. Shchurov, D. V. Blinov, N. V. Bashmakova, M. A. Polzikov, A. S. Semikhin
"... Information System for Procurement for the period from July to December 2022 inclusive. The budget impact ..."
 
Vol 13, No 2 (2020) Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation Abstract  similar documents
S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova
"... and budget impact analyses were performed. Results. The drug costs for T+O were the lowest among all ..."
 
Vol 15, No 1 (2022) Pharmacoeconomic analysis of the application of follitropin alfa in combination with assisted reproductive technologies Abstract  similar documents
K. A. Perova, D. G. Shchurov, D. V. Blinov, N. V. Bashmakova, N. Z. Musina
"... of the budget impact analysis included the costs required for the ovarian stimulation of patients distributed ..."
 
Vol 16, No 2 (2023) Comparative pharmacoeconomic analysis of follitropin delta application for superovulation induction during artificial insemination Abstract  similar documents
I. S. Krysanov, V. S. Krysanova, V. Yu. Ermakova
"... (treated separately), ART program cycle, relief of complications. As part of the budget impact analysis ..."
 
Vol 17, No 4 (2024) Economic effectiveness of fixed-dose combination of alogliptin and pioglitazone in diabetes mellitus treatment Abstract  similar documents
S. К. Zyryanov, I. N. Dyakov
"... and budget impact analysis, with consideration to the efficacy of the compared therapeutic regimens. Data ..."
 
Vol 10, No 2 (2017) COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD Abstract  similar documents
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov
 
Vol 16, No 3 (2023) Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy Abstract  similar documents
S. K. Zyryanov, I. N. Dyakov
"... and third lines of NSCLC therapy. The budget impact analysis demonstrated that if all patients in the target ..."
 
1 - 41 of 41 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)